Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "CRISIL"

8 News Found

Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL
News | September 12, 2023

Indian pharma industry to witness 8-10% revenue growth in fiscal 2024: CRISIL

Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable


Cipla scored highest among pharma companies in CRISIL’s Sustainability Rating 2022
Sustainability | May 25, 2022

Cipla scored highest among pharma companies in CRISIL’s Sustainability Rating 2022

By 2025, the company plans to achieve carbon and water neutrality, zero-waste to landfill, anti-microbial resistance stewardship and green chemistry


CRISIL positive on Krishna Institute of Medical Sciences
News | August 25, 2021

CRISIL positive on Krishna Institute of Medical Sciences

CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'


CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating
News | May 11, 2021

CRISIL assigns 'Positive' outlook to Jubilant Pharmova's long-term rating

The rating withdrawal is based on the company’s request and in line with CRISIL Rating’s policy on withdrawal of ratings.


Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO
News | January 02, 2023

Survival Technologies files DRHP with SEBI for Rs 1,000 crore IPO

The company is one of the most profitable companies manufacturing speciality chemicals in India


Sluggish exports to cap pharma revenue growth at 9% this fiscal
News | November 17, 2021

Sluggish exports to cap pharma revenue growth at 9% this fiscal

A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.


Skanray to raise Rs 400 crore to fund its inorganic growth
News | October 12, 2021

Skanray to raise Rs 400 crore to fund its inorganic growth

Since its inception, the company has either acquired or taken a majority stake in five companies


Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores
News | August 20, 2021

Emcure Pharma files DRHP for proposed IPO, offer size in the range Rs 4,500-5000 crores

In FY21, the company reported a net profit of Rs 419 crores compared to Rs 101 crores in FY 20 and consolidated total income at Rs 6092 crores, up 19% Y-o-Y